% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Alwers:148412,
author = {E. Alwers$^*$ and L. Jansen$^*$ and H. Bläker and M. Kloor
and K. E. Tagscherer and W. Roth and D. Boakye$^*$ and E.
Herpel and C. Grüllich and J. Chang-Claude$^*$ and H.
Brenner$^*$ and M. Hoffmeister$^*$},
title = {{M}icrosatellite instability and survival after adjuvant
chemotherapy among stage {II} and {III} colon cancer
patients: results from a population-based study.},
journal = {Molecular oncology},
volume = {14},
number = {2},
issn = {1878-0261},
address = {Hoboken, NJ},
publisher = {John Wiley $\&$ Sons, Inc.},
reportid = {DKFZ-2019-02967},
pages = {363-372},
year = {2020},
note = {#EA:C070#LA:C070# 14 (2), 363-372Feb 2020},
abstract = {Previous studies have reported conflicting results
regarding the benefit of administering 5-FU based
chemotherapy to colon cancer patients with microsatellite
instable (MSI-high) tumors, and results from stage-specific
analyses are scarce. Patients with stage II or III colon
cancer were recruited as part of a population-based study
between 2003 and 2015. Cox regression models including
propensity-score weighting were used to calculate hazard
ratios and confidence intervals for the association between
chemotherapy and cancer-specific (CSS), relapse-free (RFS)
and overall survival (OS) by stage of disease and MSI status
of the tumor. Median follow-up was 6.2 years. A total of
1010 colon cancer patients were included in the analysis
$(54\%$ stage II, $46\%$ stage III, $20\%$ MSI-high).
Adjuvant chemotherapy was administered to 48 $(8.7\%)$ stage
II and 366 $(79\%)$ stage III patients. Overall, patients
who received adjuvant chemotherapy had better CSS
(HR = 0.65[0.49-0.86]) than those who received surgery
alone. Among stage II patients, only 64 $(12\%)$
cancer-related deaths occurred, none of which in MSI-high
patients who received chemotherapy. Patients with MSI-high
tumors who received adjuvant treatment showed better CSS and
a tendency towards better RFS compared to MSI-high patients
who did not receive chemotherapy (HRCSS
= 0.36[0.15-0.82], HRRFS = 0.49[0.22-1.06]). Patients
with microsatellite stable (MSS) tumors receiving adjuvant
chemotherapy also had significantly better survival (HRCSS
= 0.65[0.48-0.87] and HRRFS = 0.68[0.52-0.88]). In
this population-based study including stage II and III colon
cancer patients, we observed a survival benefit of adjuvant
chemotherapy for both MSS and MSI-high tumors. Adjuvant
chemotherapy seemed to be beneficial among high-risk stage
II patients with MSI-high tumors.},
cin = {C070 / C020 / C120 / HD01},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C020-20160331 /
I:(DE-He78)C120-20160331 / I:(DE-He78)HD01-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31816156},
doi = {10.1002/1878-0261.12611},
url = {https://inrepo02.dkfz.de/record/148412},
}